News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ILEX Oncology, Inc. (ILXO) Release: FDA Advisory Committee Recommends Accelerated Clofarabine Approval For Most Common Pediatric Leukemia


10/19/2005 5:12:20 PM

ILEX(TM) Oncology, Inc. (Nasdaq:ILXO) announced today that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed clofarabine for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL). The panel advised conducting additional studies with clofarabine in acute myeloid leukemia (AML) before recommending an approval in this harder-to-treat leukemia, for which the Company also submitted data. Under the Prescription Drug User Fee Act, the FDA has until December 30, 2004 to complete the review of the clofarabine New Drug Application (NDA). The proposed branded name for clofarabine in North America is CLOLAR(TM).

Read at BioSpace.com
Read at BioSpace.com

comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES